Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4046T | ISIN: US69012T3059 | Ticker-Symbol: 41O
Tradegate
05.09.25 | 21:12
0,810 Euro
+1,38 % +0,011
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OUTLOOK THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
OUTLOOK THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7700,81006.09.
0,7790,82005.09.

Aktuelle News zur OUTLOOK THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiOutlook Therapeutics, Inc.: Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)18
DiOutlook Therapeutics, Inc. - 8-K, Current Report10
DiOutlook Therapeutics, Inc.: Outlook Therapeutics Requests Type A Meeting with FDA84ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...
► Artikel lesen
29.08.OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug16
29.08.Outlook Therapeutics stock rating downgraded by H.C. Wainwright on FDA rejection27
28.08.Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug13
28.08.FDA Rejects Outlook Therapeutics Eye Drug For Second Time10
28.08.Outlook Therapeutics' outlook dims as FDA snubs reformulated Avastin in eye disease-again4
OUTLOOK THERAPEUTICS Aktie jetzt für 0€ handeln
28.08.US FDA declines to approve Outlook Therapeutics' drug for eye condition28
28.08.Outlook Therapeutics stock falls after FDA rejects wet AMD drug10
28.08.FDA lehnt Augenmedikament ab: Aktie von Outlook Therapeutics bricht ein46
28.08.Outlook Therapeutics, Inc.: Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD242FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today...
► Artikel lesen
14.08.Outlook Therapeutics, Inc. - 10-Q, Quarterly Report37
14.08.Outlook Therapeutics, Inc. - 8-K, Current Report4
14.08.Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update429First commercial sales of LYTENAVA (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States...
► Artikel lesen
24.07.Outlook Therapeutics, Inc.: Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase28
01.07.Outlook Therapeutics, Inc. - 8-K, Current Report2
01.07.Outlook Therapeutics announces CEO appointment14
01.07.Outlook Therapeutics, Inc.: Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer246Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing...
► Artikel lesen
18.06.Outlook Therapeutics, Inc.: Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event3
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5